HRP20151019T1 - PROTUTIJELA PROTIV c-MET - Google Patents
PROTUTIJELA PROTIV c-MET Download PDFInfo
- Publication number
- HRP20151019T1 HRP20151019T1 HRP20151019TT HRP20151019T HRP20151019T1 HR P20151019 T1 HRP20151019 T1 HR P20151019T1 HR P20151019T T HRP20151019T T HR P20151019TT HR P20151019 T HRP20151019 T HR P20151019T HR P20151019 T1 HRP20151019 T1 HR P20151019T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- amino acid
- acid sequence
- monoclonal antibody
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (18)
1. Monoklonsko protutijelo protiv c-Met, ili njegov antigenski vežući fragment, naznačeno time što sadrži tri područja za određivanje komplementarnosti kod lakog lanca (LCDR) i tri područja za određivanje komplementarnosti kod teškog lanca (HCDR), gdje LCDR1 ima aminokiselinski slijed SVSSSVSSIYLH (SEQ ID NO:53), LCDR2 ima aminokiselinski slijed STSNLAS (SEQ ID NO:54), LCDR3 ima aminokiselinski slijed QVYSGYPLT (SEQ ID NO:56), HCDR1 ima aminokiselinski slijed GYTFTDYYMH (SEQ ID NO:65), HCDR2 ima aminokiselinski slijed RVNPNRRGTTYNQKFEG (SEQ ID NO:68), a HCDR3 ima aminokiselinski slijed ANWLDY (SEQ ID NO:69).
2. Monoklonsko protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevom 1, naznačeno time što se veže na epitop unutar α-lanca ljudskog c-Met i potiče internaliziranje ljudskog c-Met na površini stanice.
3. Monoklonsko protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačeno time što potiče internaliziranje ljudskog c-Met na površini stanice neovisno o hepatocitnom čimbeniku rasta (HGF).
4. Monoklonsko protutijelo, ili njegov antigenski vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeno time što se monoklonsko protutijelo, ili njegov antigenski vežući fragment, veže unutar aminokiselinskog slijeda koji se bira između:
a) 121VVDTYYDDQL130 (SEQ ID NO:77),
b) 131ISCGSVNRGTCQRHVFPHNHTADIQS156 (SEQ ID NO:78),
c) 179ALGAKVLSSVKDRFINF195 (SEQ ID NO:79) i
d) 216VRRLKETKDGFM227 (SEQ ID NO:80).
5. Monoklonsko protutijelo, ili njegov antigenski vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačeno time što se protutijelo, ili njegov antigenski vežući fragment, veže unutar aminokiselinskog slijeda koji se bira između:
a. 123DTYYDD128 (SEQ ID NO:81),
b. 144HVFPHNHTADIQS156 (SEQ ID NO:82),
c. 192FINF195 (SEQ ID NO:83) i
d. 220KETKDGFM227 (SEQ ID NO:84).
6. Monoklonsko protutijelo, ili njegov antigenski vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 5, gdje se monoklonsko protutijelo, ili njegov antigenski vežući fragment, veže na aminokiselinski slijed unutar konformacijskog epitopa, naznačenog time što uključuje 123DTYYDD128 (SEQ ID NO:81), 144HVFPHNHTADIQS156 (SEQ ID NO:82), 192FINF195 (SEQ ID NO:83) i 220KETKDGFM227 (SEQ ID NO:84).
7. Monoklonsko protutijelo, ili njegov antigenski vežući fragment, u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time što sadrži varijabilno područje lakog lanca (LCVR) i varijabilno područje teškog lanca (HCVR), gdje LCVR ima aminokiselinski slijed SEQ ID NO:5, a HCVR ima aminokiselinski slijed SEQ ID NO:17.
8. Monoklonsko protutijelo, ili njegov antigenski vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačeno time što sadrži laki lanac s konstantnim područjem κ i teški lanac s konstantnim područjem teškog lanca IgG4.
9. Monoklonsko protutijelo, ili njegov antigenski vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačeno time što sadrži laki lanac kojeg kodira polinukleotidni slijed SEQ ID NO:35 i teški lanac kojeg kodira polinukleotidni slijed SEQ ID NO:47.
10. Monoklonsko protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačeno time što sadrži dva laka lanca kojeg kodira polinukleotidni slijed SEQ ID NO:35 i dva teška lanca kojeg kodira polinukleotidni slijed SEQ ID NO:47.
11. Monoklonsko protutijelo, ili njegov antigenski vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačeno time što je aminokiselinski slijed navedenog lakog lanca istovjetan aminokiselinskom slijedu kojeg kodira polinukleotidni slijed SEQ ID NO:35; a aminokiselinski slijed navedenog teškog lanca je istovjetan aminokiselinskom slijedu kojeg kodira polinukleotidni slijed SEQ ID NO:47.
12. Monoklonsko protutijelo, ili njegov antigenski vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 8 i 10, naznačeno time što sadrži dva laka lanca, gdje je aminokiselinski slijed lakog lanca istovjetan aminokiselinskom slijedu kojeg kodira polinukleotidni slijed SEQ ID NO:35; i dva teška lanca, gdje je aminokiselinski slijed teškog lanca istovjetan aminokiselinskom slijedu kojeg kodira polinukleotidni slijed SEQ ID NO:47.
13. Monoklonsko protutijelo, ili njegov antigenski vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačeno time što sadrži laki lanac s aminokiselinskim slijedom SEQ ID NO:29 i teški lanac s konstantnim područjem teškog lanca IgG4.
14. Monoklonsko protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 8 i 13, naznačeno time što sadrži dva laka lanca s aminokiselinskim slijedom SEQ ID NO:29 i dva teška lanca s konstantnim područjem teškog lanca IgG4.
15. Farmaceutski pripravak, naznačen time što sadrži monoklonsko protutijelo, ili njegov antigenski vežući fragment, u skladu s bilo kojim od prethodnih patentnih zahtjeva, kao i farmaceutski prihvatljiv nosač, razrjeđivač ili pomoćnu tvar.
16. Monoklonsko protutijelo, ili njegov antigenski vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 14, naznačeno time što je namijenjeno upotrebi u terapiji.
17. Monoklonsko protutijelo, ili njegov antigenski vežući fragment, u skladu s bilo kojim od patentnih zahtjeva 1 do 14, naznačeno time što je namijenjeno upotrebi u liječenju raka kod čovjeka.
18. Monoklonsko protutijelo, ili njegov antigenski vežući fragment, u skladu s patentnim zahtjevom 17, naznačeno time što je navedeni rak rak želuca, bubrega, debelog crijeva, kolorektalni rak, rak glave i vrata, prostate, melanom ili rak pluća.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11682508P | 2008-11-21 | 2008-11-21 | |
| US21990309P | 2009-06-24 | 2009-06-24 | |
| EP09752708.9A EP2358755B1 (en) | 2008-11-21 | 2009-11-18 | c-MET ANTIBODIES |
| PCT/US2009/064881 WO2010059654A1 (en) | 2008-11-21 | 2009-11-18 | c-MET ANTIBODIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151019T1 true HRP20151019T1 (hr) | 2015-10-23 |
Family
ID=41435259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151019TT HRP20151019T1 (hr) | 2008-11-21 | 2009-11-18 | PROTUTIJELA PROTIV c-MET |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8217148B2 (hr) |
| EP (2) | EP2963058B1 (hr) |
| JP (1) | JP5688027B2 (hr) |
| KR (1) | KR101334450B1 (hr) |
| CN (1) | CN102216333B (hr) |
| AR (1) | AR074360A1 (hr) |
| AU (1) | AU2009316742B2 (hr) |
| BR (1) | BRPI0922800A2 (hr) |
| CA (1) | CA2743508C (hr) |
| CY (1) | CY1116886T1 (hr) |
| DK (1) | DK2358755T3 (hr) |
| EA (1) | EA020398B1 (hr) |
| ES (2) | ES2663825T3 (hr) |
| HR (1) | HRP20151019T1 (hr) |
| HU (1) | HUE026058T2 (hr) |
| IL (1) | IL212633A (hr) |
| JO (1) | JO3097B1 (hr) |
| MX (1) | MX2011005400A (hr) |
| NZ (1) | NZ592215A (hr) |
| PA (1) | PA8849001A1 (hr) |
| PL (1) | PL2358755T3 (hr) |
| PT (1) | PT2358755E (hr) |
| SI (1) | SI2358755T1 (hr) |
| TR (1) | TR201802841T4 (hr) |
| TW (1) | TWI477284B (hr) |
| WO (1) | WO2010059654A1 (hr) |
| ZA (1) | ZA201103586B (hr) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8849001A1 (es) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
| SG10201501767VA (en) | 2010-03-10 | 2015-05-28 | Genmab As | Monoclonal antibodies against c-met |
| US9169329B2 (en) * | 2010-06-01 | 2015-10-27 | Ludwig Institute For Cancer Research | Antibodies directed to the receptor tyrosine kinase c-Met |
| AU2011295919A1 (en) | 2010-08-31 | 2013-03-07 | Genentech, Inc. | Biomarkers and methods of treatment |
| EP2611928B1 (en) * | 2010-09-03 | 2016-04-27 | Academia Sinica | Anti-c-met antibody and methods of use thereof |
| DK2635602T3 (en) | 2010-11-03 | 2016-10-10 | Argen-X Nv | Anti-c-met antibodies |
| CN102276726B (zh) * | 2011-03-16 | 2014-02-19 | 常州新泉生物医药科技有限公司 | 肝细胞生长因子受体活性基团的融合蛋白 |
| US20140301989A1 (en) * | 2011-06-17 | 2014-10-09 | Brian Johnstone | Methods for increasing the potency and efficacy of stem cells |
| CA2846630A1 (en) | 2011-09-19 | 2013-03-28 | Genentech, Inc. | Combination treatments comprising c-met antagonists and b-raf antagonists |
| EP2758430A4 (en) * | 2011-09-20 | 2015-06-03 | Lilly Co Eli | ANTI-C-MET ANTIBODY |
| KR101865223B1 (ko) * | 2011-10-05 | 2018-06-08 | 삼성전자주식회사 | 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도 |
| KR20130036993A (ko) * | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체 |
| KR20130037153A (ko) * | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | 항 ｃ-Ｍｅｔ 항체 및 그의 용도 |
| WO2013064700A2 (en) | 2011-11-03 | 2013-05-10 | Argen-X B.V. | Chimeric polypeptides and methods of use |
| AU2012340826A1 (en) | 2011-11-21 | 2014-05-29 | Genentech, Inc. | Purification of anti-c-met antibodies |
| EP2785741A1 (en) | 2011-12-02 | 2014-10-08 | Cancer Research Technology Limited | Antibodies against hgf - receptor and uses |
| WO2013169532A1 (en) * | 2012-05-09 | 2013-11-14 | Eli Lilly And Company | Anti-c-met antibodies |
| CN105050618B (zh) * | 2012-06-21 | 2018-11-16 | 索伦托治疗有限公司 | 与c-Met结合的抗原结合蛋白 |
| EP2708556B1 (en) * | 2012-09-12 | 2018-11-07 | Samsung Electronics Co., Ltd | Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases |
| CN109134599A (zh) | 2012-10-12 | 2019-01-04 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其结合物 |
| HK1211235A1 (en) | 2013-02-22 | 2016-05-20 | 霍夫曼-拉罗奇有限公司 | Methods of treating cancer and preventing drug resistance |
| JP6444902B2 (ja) | 2013-03-13 | 2018-12-26 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びその結合体 |
| KR102049990B1 (ko) * | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
| KR102042174B1 (ko) * | 2013-03-29 | 2019-11-08 | 삼성전자주식회사 | 인간화 및 친화도 성숙된 항 ｃ-Ｍｅｔ 항체 및 그의 용도 |
| JP6491642B2 (ja) * | 2013-04-30 | 2019-03-27 | エージェンシー フォー サイエンス， テクノロジー アンド リサーチ | ｍＡｂ２抗Ｍｅｔ抗体 |
| SG11201600754PA (en) * | 2013-08-14 | 2016-02-26 | Qiagen Mansfield Inc | Compositions and methods for multimodal analysis of cmet nucleic acids |
| IL244623B (en) | 2013-10-14 | 2022-08-01 | Janssen Biotech Inc | Cysteine engineered fibronectin type iii domain binding molecules |
| US9717715B2 (en) | 2013-11-15 | 2017-08-01 | Samsung Electronics Co., Ltd. | Method of combination therapy using an anti-C-Met antibody |
| TW201609805A (zh) | 2013-12-23 | 2016-03-16 | 美國禮來大藥廠 | 結合ｅｇｆｒ及ｍｅｔ之多功能抗體 |
| TW201622744A (zh) | 2014-03-04 | 2016-07-01 | 美國禮來大藥廠 | 癌症之組合療法 |
| RU2016141385A (ru) | 2014-03-24 | 2018-04-28 | Дженентек, Инк. | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf |
| WO2015179835A2 (en) | 2014-05-23 | 2015-11-26 | Genentech, Inc. | Mit biomarkers and methods using the same |
| CN106687141A (zh) | 2014-09-10 | 2017-05-17 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其缀合物 |
| AU2015316522B2 (en) * | 2014-09-16 | 2021-01-21 | Symphogen A/S | Anti-met antibodies and compositions |
| ES2764299T3 (es) | 2014-12-09 | 2020-06-02 | Inst Nat Sante Rech Med | Anticuerpos monoclonales humanos contra AXL |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| WO2016149265A1 (en) * | 2015-03-16 | 2016-09-22 | Kolltan Pharmaceuticals, Inc. | Anti-met antibodies and methods of use thereof |
| WO2017019454A2 (en) * | 2015-07-28 | 2017-02-02 | Musc Foundation For Research Development | Identification of novel anti-fibrotic peptide in c-terminal region of the met receptor tyrosine kinase |
| CA3003759A1 (en) | 2015-11-03 | 2017-05-11 | Merck Patent Gmbh | Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof |
| CN106810611A (zh) * | 2015-11-30 | 2017-06-09 | 中国科学院深圳先进技术研究院 | 抗cMet和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用 |
| ES2896709T3 (es) * | 2016-02-05 | 2022-02-25 | Helixmith Co Ltd | Anticuerpos anti-c-Met y usos de los mismos |
| GB2551372A (en) * | 2016-06-16 | 2017-12-20 | Bombardier Primove Gmbh | A secondary unit, a system for inductive power transfer and a method for operating a secondary unit and a system for inductive power transfer |
| JP2019527540A (ja) | 2016-06-21 | 2019-10-03 | ヤンセン バイオテツク，インコーポレーテツド | システイン操作フィブロネクチンｉｉｉ型ドメイン結合分子 |
| CN107573416A (zh) * | 2016-06-30 | 2018-01-12 | 中国科学院深圳先进技术研究院 | 抗igf1r和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用 |
| CN107556387A (zh) * | 2016-06-30 | 2018-01-09 | 中国科学院深圳先进技术研究院 | 抗gpc3和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用 |
| CN107556388A (zh) * | 2016-06-30 | 2018-01-09 | 中国科学院深圳先进技术研究院 | 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用 |
| CN107556386A (zh) * | 2016-06-30 | 2018-01-09 | 中国科学院深圳先进技术研究院 | 抗EGFRvIII和CD3特异性双靶向抗体、含双靶向抗体表达盒的微环DNA及应用 |
| JP7016168B2 (ja) * | 2016-07-26 | 2022-02-21 | 学校法人日本大学 | 歯周炎治療薬及び歯周炎治療用組成物 |
| US10439449B2 (en) * | 2016-08-10 | 2019-10-08 | Microsoft Technology Licensing, Llc | Coupling device modules for inductive data transmission |
| MX2019003570A (es) * | 2016-09-29 | 2019-06-03 | Mitsubishi Tanabe Pharma Corp | Agentes de union monoclonales de cmet, conjugados de farmaco de los mismos y usos de los mismos. |
| TW202436356A (zh) | 2016-10-11 | 2024-09-16 | 美商艾吉納斯公司 | 抗ｌａｇ－３抗體及其使用方法 |
| US20200023072A1 (en) | 2016-10-11 | 2020-01-23 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| EP3541383B1 (en) | 2016-11-16 | 2021-01-06 | Eli Lilly and Company | Combination therapy for cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype |
| ES2875365T3 (es) * | 2016-11-23 | 2021-11-10 | Lilly Co Eli | Conjugados de fármaco de anticuerpos MET |
| US10597438B2 (en) | 2016-12-14 | 2020-03-24 | Janssen Biotech, Inc. | PD-L1 binding fibronectin type III domains |
| WO2018111978A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
| EP3554562A4 (en) | 2016-12-14 | 2020-11-04 | Janssen Biotech, Inc. | DOMAINS OF TYPE III FIBRONECTIN BINDING TO CD8A |
| US20180230218A1 (en) * | 2017-01-04 | 2018-08-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| CN106986932A (zh) * | 2017-04-06 | 2017-07-28 | 海口市人民医院 | 一种c‑Met表位肽及其应用 |
| MY192630A (en) | 2017-05-30 | 2022-08-29 | Chong Kun Dang Pharmaceutical Corp | A novel anti-c-met antibody and use thereof |
| CN109771642B (zh) | 2017-11-13 | 2022-09-20 | 同济大学苏州研究院 | c-MET激动型抗体及其用途 |
| GB201803892D0 (en) | 2018-03-12 | 2018-04-25 | Ultrahuman Six Ltd | C-met binding agents |
| AU2019272838A1 (en) | 2018-05-23 | 2020-11-26 | Adc Therapeutics Sa | Molecular adjuvant |
| MX2022002886A (es) | 2019-09-16 | 2022-04-06 | Regeneron Pharma | Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet. |
| WO2021076574A2 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
| CN119119240A (zh) | 2019-10-14 | 2024-12-13 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
| WO2022079211A1 (en) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugates |
| CA3209786A1 (en) * | 2021-02-03 | 2022-08-11 | Mythic Therapeutics, Inc. | Anti-met antibodies and uses thereof |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| US20240376214A1 (en) | 2021-04-08 | 2024-11-14 | Byondis B.V. | Anti-c-met antibodies and antibody-drug conjugates |
| EP4323409A4 (en) | 2021-04-14 | 2025-04-16 | ARO Biotherapeutics Company | CD71-BINDING FIBRONECTIN TYPE III DOMAINS |
| AU2022258584A1 (en) | 2021-04-14 | 2023-10-12 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
| CN113788895B (zh) * | 2021-10-14 | 2023-09-15 | 陕西健吉跃生物科技有限公司 | 一种兔多克隆抗体及其制备方法和应用 |
| EP4426727A2 (en) | 2021-11-03 | 2024-09-11 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
| TW202500584A (zh) | 2023-05-19 | 2025-01-01 | 法商施維雅藥廠 | 抗met抗體、抗體-藥物結合物、組合物及其用途 |
| WO2025025434A1 (zh) * | 2023-08-02 | 2025-02-06 | 百泰生物药业有限公司 | EGFR/c-Met双特异性抗体及其应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP3293823B2 (ja) * | 1991-05-10 | 2002-06-17 | フアルマシア・エ・アツプジヨン・エツセ・ピー・アー | 肝細胞成長因子（ｈｇｆ）レセプターの部分切除形態 |
| US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| US6214344B1 (en) * | 1995-06-02 | 2001-04-10 | Genetech, Inc. | Hepatocyte growth factor receptor antagonists and uses thereof |
| WO2000064946A2 (en) | 1999-04-28 | 2000-11-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| WO2004072117A2 (en) * | 2003-02-13 | 2004-08-26 | Pharmacia Corporation | Antibodies to c-met for the treatment of cancers |
| US20040208876A1 (en) * | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
| ITMI20031127A1 (it) * | 2003-06-05 | 2004-12-06 | Uni Degli Studi Del Piemont E Orientale Am | Anticorpi anti-hgf-r e loro uso |
| HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| KR100556660B1 (ko) * | 2003-11-11 | 2006-03-10 | 국립암센터 | Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체 |
| EP1692178A1 (en) | 2003-12-11 | 2006-08-23 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
| US20050227324A1 (en) | 2003-12-19 | 2005-10-13 | Genentech, Inc. | Monovalent antibody fragments useful as therapeutics |
| ZA200701656B (en) | 2004-08-05 | 2008-09-25 | Genentech Inc | Humanized anti-cment antagonists |
| KR20080000613A (ko) | 2005-03-25 | 2008-01-02 | 제넨테크, 인크. | 과안정화된 ｃ-ｍｅｔ의 조절을 위한 방법 및 조성물 |
| SI1981981T1 (sl) | 2006-02-06 | 2012-01-31 | Metheresis Translational Res Sa | Anti-met monoklonalno protitelesce, njegovi fragmenti in vektorji, za zdravljenje tumorjev in ustrezni proizvodi |
| CA2638869A1 (en) * | 2006-02-22 | 2007-09-07 | Eli Lilly And Company | Humanized anti-ghrelin antibodies |
| TW200815470A (en) * | 2006-03-30 | 2008-04-01 | Novartis Ag | Compositions and methods of use for antibodies of c-Met |
| KR100829972B1 (ko) * | 2006-07-14 | 2008-05-16 | 재단법인서울대학교산학협력재단 | 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법 |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2118318B1 (en) * | 2007-02-08 | 2012-08-08 | The Regents of the University of California | Gnaq mutations in melanoma |
| EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| PA8849001A1 (es) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
-
2009
- 2009-11-13 PA PA20098849001A patent/PA8849001A1/es unknown
- 2009-11-15 JO JOP/2009/0424A patent/JO3097B1/ar active
- 2009-11-16 AR ARP090104438A patent/AR074360A1/es unknown
- 2009-11-17 TW TW098139025A patent/TWI477284B/zh not_active IP Right Cessation
- 2009-11-18 CN CN200980146173.1A patent/CN102216333B/zh active Active
- 2009-11-18 PL PL09752708T patent/PL2358755T3/pl unknown
- 2009-11-18 DK DK09752708.9T patent/DK2358755T3/en active
- 2009-11-18 MX MX2011005400A patent/MX2011005400A/es active IP Right Grant
- 2009-11-18 SI SI200931262T patent/SI2358755T1/sl unknown
- 2009-11-18 TR TR2018/02841T patent/TR201802841T4/tr unknown
- 2009-11-18 HR HRP20151019TT patent/HRP20151019T1/hr unknown
- 2009-11-18 BR BRPI0922800A patent/BRPI0922800A2/pt not_active IP Right Cessation
- 2009-11-18 ES ES15175051.0T patent/ES2663825T3/es active Active
- 2009-11-18 EA EA201170716A patent/EA020398B1/ru not_active IP Right Cessation
- 2009-11-18 NZ NZ592215A patent/NZ592215A/xx not_active IP Right Cessation
- 2009-11-18 ES ES09752708.9T patent/ES2549760T3/es active Active
- 2009-11-18 CA CA2743508A patent/CA2743508C/en not_active Expired - Fee Related
- 2009-11-18 US US12/620,617 patent/US8217148B2/en active Active
- 2009-11-18 HU HUE09752708A patent/HUE026058T2/en unknown
- 2009-11-18 WO PCT/US2009/064881 patent/WO2010059654A1/en active Application Filing
- 2009-11-18 JP JP2011537557A patent/JP5688027B2/ja active Active
- 2009-11-18 PT PT97527089T patent/PT2358755E/pt unknown
- 2009-11-18 AU AU2009316742A patent/AU2009316742B2/en not_active Ceased
- 2009-11-18 KR KR1020117011522A patent/KR101334450B1/ko not_active Expired - Fee Related
- 2009-11-18 EP EP15175051.0A patent/EP2963058B1/en active Active
- 2009-11-18 EP EP09752708.9A patent/EP2358755B1/en active Active
-
2011
- 2011-05-02 IL IL212633A patent/IL212633A/en not_active IP Right Cessation
- 2011-05-16 ZA ZA2011/03586A patent/ZA201103586B/en unknown
-
2012
- 2012-06-25 US US13/531,858 patent/US8398974B2/en active Active
-
2015
- 2015-10-02 CY CY20151100880T patent/CY1116886T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151019T1 (hr) | PROTUTIJELA PROTIV c-MET | |
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| HRP20191462T1 (hr) | Antitijela usmjerena protiv her-3 i njihove uporabe | |
| JP2012509881A5 (hr) | ||
| CN110366560A (zh) | 抗b7-h4抗体、其抗原结合片段及其医药用途 | |
| RU2018120695A (ru) | Связывающие молекулы, специфичные в отношении asct2, и их применения | |
| HRP20160485T1 (hr) | Anti-mezotelinska protutijela i njihova uporaba | |
| ME02798B (me) | Protutijela protiv dkk-1" | |
| HRP20160151T1 (hr) | PROTUTIJELA PROTIV N3pGlu-AMILOIDNOG BETA PEPTIDA I NJIHOVA UPOTREBA | |
| HRP20171992T1 (hr) | Protutijela protiv cgrp | |
| RU2018145852A (ru) | Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение | |
| HRP20140108T1 (hr) | Protutijela protiv sklerostina | |
| NZ598391A (en) | Anti-hepcidin antibodies and uses thereof | |
| NZ609619A (en) | Novel egfr-binding molecules and immunoconjugates thereof | |
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| JP2015535828A5 (hr) | ||
| JP2016135783A5 (hr) | ||
| JP2012532851A5 (hr) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| RU2010107175A (ru) | Антитела человека к cd20 человека и способ их использования | |
| RS53661B1 (en) | HIGH AFINITY ANTIBODY ANTIBODIES TO THE HUMAN NERVOUS FACTOR OF GROWTH | |
| RU2013125306A (ru) | Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование | |
| RU2016138744A (ru) | Антитела, фармацевтические композиции и их применения | |
| JP2017512759A5 (hr) |